Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
Frédérique Bard(Sunesis (United States)), Catherine Cannon(Sunesis (United States)), Robin Barbour(Sunesis (United States)), Rae-Lyn Burke(Sunesis (United States)), Dora Games(Sunesis (United States)), Henry Grajeda(Sunesis (United States)), Teresa Guido(Sunesis (United States)), Kang Hu(Sunesis (United States)), Jiping Huang(Sunesis (United States)), Kelly Johnson‐Wood(Sunesis (United States)), Karen Khan(Sunesis (United States)), Dora Kholodenko(Sunesis (United States)), Mike Lee(Sunesis (United States)), Ivan Lieberburg(Sunesis (United States)), Ruth Motter(Sunesis (United States)), Minh Dang Nguyen(Sunesis (United States)), Ferdie Soriano(Sunesis (United States)), Nicki Vasquez(Sunesis (United States)), Kim Altman Weiss(Sunesis (United States)), Brent Welch(Sunesis (United States)), Peter Seubert(Sunesis (United States)), Dale Schenk(Sunesis (United States)), Ted Yednock(Sunesis (United States))
Cited by 2,002Open Access
Abstract
Related Papers
Amyloid precursor protein processing and Aβ <sub>42</sub> deposition in a transgenic mouse model of Alzheimer disease
Kelly Johnson‐Wood, M. Lee, Ruth Motter et al.|Proceedings of the National Academy of Sciences|1997|658